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Abstract
Objective: Cardiovascular disease (CVD) is rising in low and middle-income
countries, but studies of CVD epidemiology in such settings often focus on risk
factors rather than measures of disease progression. Here we use the ankle brachial
index (ABI) to assess the prevalence of peripheral artery disease (PAD) among
older women living in Metropolitan Cebu, Philippines, and relationships between
ABI and CVD risk factors and body composition.
Methods: ABI was measured using the Doppler technique in 538 female partici-
pants in the 2015 Cebu Longitudinal Health and Nutrition Survey (mean age
58 years, range 47-78 years). ABI was related to a panel of CVD risk factors mea-
sured in 2005 and 2012, and to 2012 body composition measures.
Results: The prevalence of PAD (1.8%) was among the lowest reported in any
comparably-aged sample, and only 9.9% of participants had an ABI indicating bor-
derline PAD risk. Smoking (P < 0.011) and use of CVD medications (P < 0.0001)
predicted lower ABI (indicating higher PAD risk), which was also lower in relation
to 2012 systolic blood pressure (P < 0.054). ABI was unrelated to other CVD risk
factors. An apparent protective relationship between body mass index (BMI) and
ABI, noted in previous studies, was found to be confounded by protective relation-
ships between ABI and fat free mass, height, and grip strength (all P < 0.05).
Conclusions: The prevalence of PAD is low in Cebu Longitudinal Health and
Nutrition Survey participants, and ABI was related to few CVD risk factors. Past
reports of lower PAD risk in relation to BMI may reflect confounding by lean
mass, which has protective relationships with ABI.
1 | INTRODUCTION
Cardiovascular disease (CVD) is a leading cause of morbid-
ity and mortality worldwide (Lozano et al., 2012; Roth et al.,
2015), and CVD-related deaths are projected to rise from
16.7 million in 2002 to 23.3 million in 2030 (Mathers &
Loncar, 2006). This increase is particularly dramatic in low-
and middle-income countries in Southeast Asia that are
undergoing nutrition and lifestyle transitions, with rising
rates of overweight and obesity contributing to the increas-
ing burden of chronic metabolic disease (Popkin, 2001).
Despite this growing CVD burden, most studies examin-
ing the etiology of metabolic disease in this context focus on
intermediary risk factors such as lipids, glucose, and blood
pressure rather than measuring disease progression itself.
While direct measures such as coronary artery calcification
tests are effective in capturing disease progression, their cost
and reliance on imaging equipment limits their utility in
field-based studies (Wexler et al., 1996). In contrast, ankle
brachial index (ABI) is a noninvasive and field-friendly
measure that captures the progression of atherosclerosis in
the lower limbs in both symptomatic and asymptomatic
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individuals (Aboyans et al., 2012). Arterial stiffening in the
lower limbs—also referred to as peripheral artery disease
(PAD)—is a leading cause of cardiovascular mortality
with a growing global prevalence (Caro, Migliaccio-Walle,
Ishak, & Proskorovsky, 2005; Criqui et al., 1992; Fowkes
et al., 2016). ABI is thus a potentially useful tool for inves-
tigating the impact of rapid nutritional and lifestyle change
on the development of atherosclerosis in community-based
settings around the world.
The Philippines is a lower-middle-income country in
Southeast Asia where cardiovascular risk factors, including
overweight and obesity, are changing in the context of a
transitioning economy marked by increasing urbanization
(Adair, 2004; World Bank, 2018). In a recent Philippines
national survey of more than 19 000 adults aged 20 and above,
only 0.1% reported a history of PAD (FNRI-DOST, 2015b).
However, 83.4% of the sample had never heard of the disease
and costs associated with diagnosing the condition may often
be prohibitive. Here we use Doppler ultrasound measured ABI
to characterize PAD progression among women (48-79 years
old) participating in a study of aging in Metropolitan Cebu,
Philippines. Our past work tracked the emergence of CVD risk
factors among this cohort as they aged, including evidence for
secular trends, and explored the role of changes in diet and
weight gain (Adair, Kuzawa, McDade, Carba, & Borja, 2018).
Our goals in the present analyses are to use ABI, measured in
2015, to describe the prevalence of PAD in this population, and
to report links between the ABI and a panel of CVD risk factors
and body composition measures obtained in 2012 and 2005.
2 | METHODS
The Cebu Longitudinal Health and Nutrition Survey
(CLHNS) began in 1983 with recruitment of 3327 pregnant
women from randomly selected urban and rural neighbor-
hoods in Metropolitan Cebu, Philippines (Adair et al., 2011).
The analyses presented in this article include data collected
among these women during follow-up surveys in 2005 and
2012, which are related to ABI measured in 2015. Socioeco-
nomic, demographic, health behavior, and anthropometric
information were collected during in-home interviews. Com-
plete ABI, anthropometric, and sociodemographic data were
available on a subsample of 538 participants. When com-
pared to women visited in 2012 but excluded from the ABI
analysis, the ABI subsample was slightly heavier (57.2 kg vs
55.9, P < 0.031), had a higher BMI (25.3 vs 24.7 kg/m2,
P < 0.011) and waist circumference (WC; 83.0 vs 81.6 cm,
P < 0.03), and had borderline lower HbA1c (5.8 vs 5.9%,
P < 0.07), but had similar household assets, heights, systolic
and diastolic blood pressures, and total and HDL cholesterol
levels (all P > 0.1). We also assessed whether the ABI anal-
ysis subsample had CVD risk factors measured in 2005
(10 years prior to ABI measurement) that differed from
women excluded from the study. In 2005, the women
included in the ABI analyses had modestly lower systolic
blood pressure (118.4 vs 120.1 mm Hg, P < 0.093), dia-
stolic blood pressure (78.7 vs 80.0 mm Hg, P < 0.048), and
fasting glucose (95.4 vs 101.1 mg/dL, P < 0.002), but had
similar total cholesterol, HDL cholesterol, and C-reactive
protein (CRP; all P > 0.13). All research was conducted
under conditions of written informed consent with Institu-
tional Review Board oversight by the University of North
Carolina, Chapel Hill and the University of San Carlos.
2.1 | Behavioral and socioeconomic data
Socioeconomic status was indexed by a household assets
scale reflecting whether the family had electricity, owned
homes made of strong material, owned an air conditioner,
refrigerator, TV, vehicle and other appliances. Women were
also asked about their highest completed level of education.
Women were defined as smokers if they reported smoking at
least 1 cigarette daily.
2.2 | Medication use
During the 2012 interview, women were asked about each
medication that they were currently taking, and were classi-
fied as taking a CVD-related drug if they were taking any
drug included in MIMS classification for treatment of CVDs
(MIMS 200-299): cardiac drugs, anti-anginal drugs, anti-
hypertensives (eg, diuretics, beta blockers), peripheral vasodi-
lators and cerebral activators, vasoconstrictors, dyslipidemic
agents, hemostatics, anticoagulants, antiplatelets and fibrino-
lytics (thrombolytics), phlebitis and varicose preparations,
hemorrheologicals, hematopoietic agents, other cardiovascular
drugs, along with insulin preparations (MIMS 1101), and anti-
diabetic agents (MIMS 1102).
2.3 | Anthropometry, body composition, and grip
strength
In 2005 and 2012, weight, height, and WC were measured
using standard techniques (Lohman, Roche, & Martorell,
1991). The body mass index (BMI) was calculated as kg/m2,
and individuals were classified as overweight if BMI > 25
kg/m2 or obese if BMI > 30 kg/m2. In 2012, we also
obtained estimates of percentage body fat using a Tanita bio-
electrical impedance scale (algorithms adjusted for Asian
populations), which was used (along with weight) to calculate
fat mass and fat-free mass. Grip strength was measured with a
Smedley-type dynamometer in triplicate in each hand. Left
and right grip strengths were defined as the highest reading
for that hand. In analyses, we included grip strength of the
dominant hand, defined as the hand with the stronger reading.
2.4 | Ankle-brachial index
The ABI protocol was administered as part of the 2015
CLHNS round. ABI recruitment was limited to women who
had participated in the 2005 (and who provided biomarker
data), 2012, and 2015 surveys. Because the protocol required
ABI to be measured in health centers, we only recruited
mothers who had already attended clinic sessions as part of
the 2012 CLHNS flu vaccination protocol. ABI measurements
and calculations followed the standard procedure detailed by
the American Heart Association (Aboyans et al., 2012).
Trained technicians conducted the ABI measurements at a
health center near participants' homes during the 2015 follow-
up. They measured systolic blood pressure twice at each ankle
and at the brachial artery in each arm using the Doppler tech-
nique (Hadeco ES100V3 Bidop Arterial and Venous Doppler
with Smart V-Link software). The ABI was calculated as the
ratio of systolic blood pressure measured at the ankle to that
measured at the brachial artery in the upper arm, averaging
the two measures for each limb and using the arm with the
highest blood pressure measurement. ABI values ≤0.90 indi-
cate that an individual has PAD and is at high risk for future
cardiac events such as myocardial infarction. ABI values that
are >0.90 but ≤1.0 indicate increased risk for PAD and mod-
erate risk for future cardiac events (Aboyans et al., 2012).
High ABI values (>1.4) are interpreted as evidence for arterial
stiffening due to calcification (Resnick, 2004).
2.5 | Blood pressure
Systolic and diastolic blood pressures were measured in trip-
licate, after 10 minutes of seated rest, by trained research
staff using appropriate cuff sizes, and using OMRON HEM-
7211 blood pressure monitors. Following International Dia-
betes Foundation guidelines (Alberti, Zimmet, Shaw, &
Grundy, 2006), individuals were classified as having ele-
vated blood pressure (EBP) if they met one or more of the
following criteria: systolic blood pressure ≥130 mm Hg,
diastolic blood pressure ≥85 mm Hg, or taking antihyperten-
sive medications.
2.6 | C-reactive protein (CRP)
In 2005, venipuncture blood samples were collected using
EDTA-coated vacutainer tubes in the participants' homes in
the morning after the overnight fast. Blood samples were kept
in coolers on ice packs for no more than 2 hours and were
then centrifuged to separate plasma prior to freezing at −35C.
Samples were express-shipped in a single batch to Northwest-
ern University on dry ice and stored frozen at −80C until
analysis at the clinical chemistry facility at Northwestern
Memorial Hospital in Evanston. CRP concentrations were
determined using a high sensitivity immunoturbidimetric method
(Synchron LX20, lower detection limit: 0.1 mg/L). In 2012,
finger stick capillary blood samples were collected on filter
paper for analysis of CRP. The participant's finger was
cleaned with alcohol, and a sterile, disposable microlancet
was used to extract drops of blood that were applied to
filter paper (McDade, Williams, & Snodgrass, 2007). After
collection, DBS cards were dried for at least 4 hours before
being stored in sealed bags at −20C until express shipment to
Northwestern University, where they were stored and ana-
lyzed (see McDade, Borja, Kuzawa, Perez, & Adair, 2015 for
details). DBS samples were analyzed for CRP in the Labora-
tory for Human Biology Research using a modified high sen-
sitivity enzyme immunoassay protocol previously developed
for use with DBS (McDade, Burhop, & Dohnal, 2004). CRP
was analyzed as a continuous variable and was also used to
classify individuals as having high CRP, defined as a CRP ≥3
(but less than 10, which may be interpreted as an active
infection; Pearson et al., 2003).
2.7 | Measures of glucose control
In 2005, fasting glucose was measured at the time of veni-
puncture with one drop of blood using a portable glucose
meter (One Touch Ultra Blood Glucose Monitoring System,
Johnson and Johnson) and with values corrected to align with
capillary samples (for further protocol details see Norris et al.,
2012), and with diabetes defined as a value ≥7 mmol/L. In
2012, HbA1c was measured in capillary finger prick blood
samples using the NycoCard Reader II, with diabetes defined
as an A1c value of at least 6.5% (International Expert Com-
mittee, 2009).
2.8 | Lipid profiles
In 2005, lipid profiles were measured in plasma collected
after an overnight fast, and were shipped frozen on dry ice to
the Emory Lipid Research Laboratory for analysis. Total
lipids were determined by enzymatic methods using reagents
from Beckman Diagnostics (Palo Alto, California) on a CX5
chemistry analyzer. HDL cholesterol was determined using
the homogenous assay for direct HDL cholesterol (Genzyme
Corporation, Exton, Pennsylvania). In 2012, nonfasting lipid
profiles (total cholesterol, HDL cholesterol) were measured
in capillary finger prick blood samples using the CardioChek
point-of-care system, which has been validated against
venous blood measures (Ferreira et al., 2015).
2.9 | Statistical analyses
We first calculated descriptive statistics for ABI to compare
the prevalence of PAD among women in the present sample
with findings from previous studies. We then ran a series of
predictive regression models aimed at clarifying the links
between ABI and body composition measures. The first
model adjusted only for age. Because ABI was significantly
lower among smokers (1.046 +/ 0.114 vs 1.078 ± 0.073;
P < 0.011) and among individuals taking medications for
CVDs (1.049 +/ 0.113 vs 1.081 ± 0.067; P < 0.0001), we
ran a second model adjusted for both. We also included an
assets scale in this model, which was not a significant pre-
dictor of ABI (P < 0.21) but did modify model coefficients.
To assess the possible role of lean tissue and strength on
ABI, the third, fourth, and fifth models built on model 2 and
alternatively included height, fat free mass and grip strength.
Finally, we ran regression models (model 1 adjusting only
for age, model 2 adjusting for age, smoking status, use of
CVD-related drugs and household assets) linking a series of
CVD risk factors measured in 2005 and 2012, and risk factor
status (overweight or obese, diabetic, EBP, and elevated
CRP), with ABI measured in 2015. Models linking CRP to
ABI were run after excluding individuals whose CRP levels
were above 10, suggesting an active infection. All analyses
were performed using Stata version 13.1 for IBM (StataCorp,
College Station, Texas).
3 | RESULTS
This study describes ABI measured in 2015 in relation to
CVD risk factors and other covariates measured in 2012 and
2005. The mean ABI of the sample (age 58.2 ± 5.8 years,
range 47.5, 78.7 years) was 1.08 ± 0.08 (range 0.54, 1.38).
Characteristics of the sample during the 2005 and 2012 sur-
veys are presented in Table 1. Ten participants (1.86% of the
sample) had ABI values ≤0.90 indicating current PAD, and
no participants had elevated ABI (ABI > 1.4) consistent
with arterial stiffening (Figure 1). Fifty-three participants
(9.9% of the sample) were classified as having borderline
risk for PAD with ABI values >0.90 and ≤1.0, and the
remaining 475 participants (88.3% of the sample) were at
low risk for PAD with ABI values >1.0. There was no indi-
cation that ABI or PAD risks were increased at older ages
(Figure 2). Among the 19 individuals who were 70 or older,
the mean ABI was 1.039 (SD 0.094) and two (10.5%) had
an ABI consistent with PAD. Considered on their own,
smoking status (−0.032 ± 0.013; P < 0.011) and cardiovas-
cular medication use (−0.032 ± 0.009; P < 0.0001) were
significant predictors of lower ABI, but ABI was not signifi-
cantly related to the woman's age (in years) at ABI measure-
ment (−0.001 ± 0.0006; P < 0.121) or her household assets
score (scale range 1-11; 0.003 ± 0.002; P < 0.209).
Results of linear regression models predicting ABI as a
continuous variable are shown in Tables 2–4. After adjustment
for age, household assets, smoking status and CVD-related
drug use, BMI, WC, and fat mass measured in 2012 were all
positively related to ABI (each run separately), consistent with
a weak protective relationship. Although none of these rela-
tionships were significant, the P-value for all was <0.2 and fat
mass was a borderline significant (P < 0.059) positive predic-
tor of ABI. We next added, sequentially, height, fat free mass,
and grip strength to the adjusted models to evaluate the poten-
tial role of fat free mass or strength as confounders. Height, fat
free mass, and grip strength were all significant or borderline
significant positive predictors of ABI in these models, and
adjusting for these relationships substantially attenuated the
relationships between ABI and the BMI, WC, and fat mass.
We next ran models assessing relationships between ABI
and a panel of cardiovascular risk factors measured in 2012.
TABLE 1 Characteristics of sample in 2005 and 2012 (N = 538)
2005 2012
Variable Mean (SD) Range Mean (SD) Range
Age (years) 47.9 (5.9) (37.2, 69.3) 55.2 (5.8) (44.5, 75.9)
Height (cm) 150.5 (4.8) (138.6, 168.8) 150.3 (4.8) (138.1, 167.6)
Weight (kg) 56.0 (10.5) (31, 92.3) 57.2 (11.4) (31.3, 103.1)
BMI (kg/m2) 24.7 (4.2) (14.5, 38.3) 25.3 (4.6) (14.2, 42.9)
Waist circum. (cm) 82.3 (10.4) (59, 118.4) 83.0 (11.4) (51.4, 123.3)
Overweight (%) 36.4% 39.0%
Obese (%) 9.9% 13.2%
Smoker (%) 7.4%
Grades completed 6.9 (3.2) (0, 17)
Taking CVD drug (%) 16.2%
Systolic blood pressure (mm Hg) 118.4 (18.1) (80, 190) 127.7 (20.1) (82.3, 194.7)
Diastolic blood pressure (mm Hg) 78.7 (11.6) (50, 120) 75.9 (11.7) (44.3, 117.7)
Elevated blood pressure (%)a 38.3% 47.1%
CRP (mg/L) 2.43 (6.43)b (0.05, 122.6) 2.06 (3.13) (0.02, 47.9)
Total cholesterol (mg/dL) 187.7 (37.9)c (89, 393) 199.7 (37.7) (108, 379)
HDL cholesterol (mg/dL) 40.3 (10.0)c (15.7, 80.7) 43.6 (12.9) (17, 94)
Hba1c (%) 5.8 (1.2) (4.4, 13.4)
Glucose (mmol/L) 5.30 (1.64) (3.36, 20.03)
Diabetic (%)d 5.4% 10.0%
aSystolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or taking antihypertensive medications.
bn = 535.
cn = 536.
dFasting glucose ≥7 mmol/L (2005) and Hba1c ≥6.5% (2012).
Model 1 adjusted only for age while model 2 adjusted for
age, household assets, smoking status, and CVD-related
drug use. Models explained relatively little variance in ABI:
all model 1 adjusted R2 were less than 0.015, whereas model
2 adjusted R2 varied from 0.032 to 0.036 (not shown). Of
the factors considered, only systolic blood pressure and the
closely-related measure of EBP were significant predictors
of lower ABI (high PAD risk) in minimally-adjusted models.
After additional adjustments in model 2, systolic blood
pressure dropped to a borderline significant relationship
(P < 0.053) and EBP was no longer significant (P > 0.2).
No other CVD risk factors predicted ABI in minimally or
fully adjusted models. Table 4 reports results of comparable
models linking ABI to CVD risk factors measured in 2005;
only systolic blood pressure was a significant predictor in
unadjusted models, and no CVD risk factor predicted ABI in
adjusted models.
4 | DISCUSSION
In this aging cohort of women from Cebu, Philippines, we find
a relatively high average ABI, and corresponding low preva-
lence of PAD, compared with most prior studies of similarly-
aged women. Risk for PAD was increased in relation to
systolic blood pressure, and among smokers and individuals
TABLE 2 Standardized regression coefficients from regression models linking 2012 body composition to 2015 ABIa
Base modelb Adjusted modelc +Height +FFM +Grip strength
BMI (kg/m2) 0.044 (0.044) 0.060 (0.045) 0.054 (0.045) −0.032 (0.062) 0.034 (0.047)
Height (cm) 0.092 (0.043)*
Fat free mass (kg) 0.134 (0.062)*
Grip strength (kg) 0.102 (0.046)*
Model adj. R2 0.003 0.035 0.041 0.041 0.042
Waist circumference 0.065 (0.043) 0.085 (0.045) 0.068 (0.046) 0.008 (0.065) 0.064 (0.046)
Height (cm) 0.082 (0.044)^
Fat free mass (kg) 0.106 (0.066)
Grip strength (kg) 0.096 (0.045)*
Model adj. R2 0.0049 0.038 0.043 0.041 0.044
Fat mass (kg) 0.050 (0.044) 0.066 (0.045) 0.046 (0.046) −0.030 (0.065) 0.038 (0.047)
Height (cm) 0.085 (0.044)^
Fat free mass (kg) 0.134 (0.065)*
Grip strength (kg) 0.100 (0.046)*
Model adj. R2 0.0032 0.035 0.040 0.040 0.042
aStandardized regression coefficients (SE)––interpreted as SD difference in ABI predicted by 1-SD change in predictor (continuous variables); *P < 0.05, P̂ < 0.1;
FFM, fat free mass.
bAdjusted for maternal age (coefficient not shown).
cAdjusted for maternal age, highest education level, smoking status and use of cardiovascular drugs.
FIGURE 1 Distribution of ankle-brachial index (ABI) values for women
in the Cebu Longitudinal Health and Nutrition Survey. aRisk categories
(Aboyans et al., 2012): “Low Risk” = ABI >1.0, “Borderline Risk” = 0.90 <
ABI ≤1.0, “High Risk” = ABI ≤0.90. High risk values indicate diagnosable
















FIGURE 2 Distribution of ABI by age category among Cebu women.
Sample sizes for the four groups (in order of ascending age) were 22, 332,
165, and 22
taking medications for CVDs, but was unrelated to most bio-
markers of CVD risk measured at two time points in the years
preceding ABI measurement. Women who were taller or who
had a greater fat free mass had an ABI consistent with lower
PAD risk, but the ABI was unrelated to measures of adiposity.
These findings point to an unusually low burden of PAD in
the context of a population undergoing the nutrition transition
and rising CVD (FNRI-DOST, 2015a; Pedro, Barba, &
Leon, 2007).
Only 10 participants in the present study (1.9%) had
ABI values indicating current PAD. The only study of a
similarly-aged cohort that we are aware of that reported a
lower prevalence was a study of forager-horticulturalists liv-
ing in lowland Bolivia, in which no participants had an ABI
consistent with PAD (Gurven et al., 2009). The lowest preva-
lence according to ABI values recorded in a meta-analysis
conducted by Fowkes, Murray, and Butcher (2008) was 2.8%
reported in 20 to 74 year old women (N = 838) participating
in the San Luis Valley Diabetes Study in Colorado. In a recent
review of studies measuring ABI among countries in Sub-
Saharan Africa, Johnston et al. (2016) found a range of PAD
prevalence ranging from 3.1% in a rural horticulturalist popu-
lation in Ghana to 52.2% for a sample of older adults with
diabetes in Nigeria. Across Asia, studies have reported ABI
levels consistent with PAD in 11% of women in Hong Kong
(age 72.6 ± 5.4 years), 17.7% in Beijing (male and female
mean age 68.5 ± 5.4 years), and 8.6% in Thailand (age
range 52-73 years; He et al., 2006; Sritara et al., 2007; Woo
et al., 2006).
We found that ABI was not related to age in the CLHNS
sample, and there was also minimal evidence for links
between other CVD risk factors and ABI. Of the panel of
CVD risk factors that we considered, only systolic blood pres-
sure (and the closely related measure of EBP), measured
3 years prior to ABI measurement, was a borderline signifi-
cant predictor of lower ABI. In contrast to findings in most
other studies, we found that lipid profiles, measures of glu-
cose control and diabetes status, and inflammation were not
significant predictors of ABI, with or without additional
controls for socioeconomic and other factors. This pattern of
findings is most consistent with the study of Tsimane forager-
horticulturalists from lowland Bolivia noted above. In this
sample PAD was completely absent in all age groups, and the
ABI was found to be unrelated to the BMI or obesity, lipid
profiles, systolic blood pressure and several measures of
inflammation (Gurven et al., 2009). Of the CVD risk factors
considered, only diastolic blood pressure was a significant,
inverse predictor of ABI. The authors of the Tsimane study
speculate that physical activity, genetic variants specific to
Amerindian populations, or differences in infectious disease
ecology, such as chronic exposure to helminths, could protect
the population against PAD. Our prior work with the CLHNS
has shown that early life infectious or microbial exposures pre-
dict lower CRP in the adult offspring of the mothers included
in this study, which could point to differences in inflammatory
regulation among CLHNS participants (McDade, Rutherford,
Adair, & Kuzawa, 2010). Although speculative, a higher
ambient pathogen exposure in the Tsimane and Cebu samples,
compared to other samples that have been the focus of work
on PAD, may limit the prevalence of PAD.
Consistent with prior studies (reviewed in Criqui &
Aboyans, 2015), we found that adiposity measures such as
the BMI, WC, and fat mass were not significant predictors
of the ABI in fully adjusted models. It is notable that, when
assessed on their own, all three measures were weakly
TABLE 3 Standardized regression coefficients from models relating ABI
(2015) to individual cardiovascular disease risk factors (2012)a
Base modelsb Adjusted modelsc
Systolic blood pressure −0.120 (0.043)** −0.085 (0.044)^
Diastolic blood pressure −0.041 (0.043) −0.012 (0.043)
Elevated blood pressured −0.203 (0.087)* −0.11 (0.093)
CRPe −0.102 (0.081) −0.113 (0.081)
High CRPe,f −0.085 (0.112) −0.111 (0.112)
Total cholesterol −0.035 (0.043) −0.034 (0.043)
HDL cholesterol −0.026 (0.043) −0.036 (0.043)
HbA1c −0.037 (0.043) −0.019 (0.043)
Diabeticg −0.127 (0.143) −0.027 (0.146)
aStandardized regression coefficients (SE)––interpreted as SD difference in ABI
predicted by 1-SD change in predictor (continuous variables) and SD difference
in ABI predicted by risk category status (categorical variables) **P < 0.01,
*P < 0.05, P̂ < 0.1.
bAdjusted for maternal age (coefficient not shown).
cAdjusted for maternal age, highest education level, smoking status and use of
cardiovascular drugs (coefficients not shown).
dSystolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or
taking antihypertensive medications.
eExcludes 7 individuals with CRP ≥10 mg/dL.
fCRP ≥3.
gHba1c ≥6.5%.
TABLE 4 Standardized regression coefficients from models relating ABI
(2015) to individual cardiovascular disease risk factors (2005)a
Base modelsb Adjusted modelsc
Systolic blood pressure −0.104 (0.044)* −0.054 (0.047)
Diastolic blood pressure −0.044 (0.044) −0.004 (0.045)
Elevated blood pressured −0.130 (0.089) −0.021 (0.093)
CRPe −0.071 (0.131) −0.041 (0.129)
High CRPe,f 0.004 (0.110) 0.016 (0.108)
Total cholesterol −0.051 (0.044) −0.053 (0.043)
HDL cholesterol 0.040 (0.043) 0.034 (0.043)
Glucose −0.041(0.043) −0.027 (0.043)
Diabeticg −0.210 (0.191) −0.118 (0.191)
aStandardized regression coefficients (SE)––interpreted as SD difference in ABI
predicted by 1-SD change in predictor (continuous variables) and SD difference
in ABI predicted by risk category status (categorical variables); beta coefficient
(SE) **P < 0.01, *P < 0.05, P̂ < 0.1.
bAdjusted for maternal age (coefficient not shown).
cAdjusted for maternal age, highest education level, smoking status, and use of
cardiovascular drugs (coefficients not shown).
dSystolic blood pressure ≥130 mm Hg, diastolic blood pressure ≥85 mm Hg, or
taking antihypertensive medications.
eExcludes 15 individuals with CRP ≥10 mg/dL.
fCRP ≥3.
gFasting glucose ≥7 mmol/L.
positively related to ABI, suggesting weak protective rela-
tionships with ABI and PAD risk, with WC closest to signif-
icance (P < 0.136). Despite robust evidence for a link
between adiposity or obesity and CVD (Hajer, Haeften,
W, & Visseren, 2008), a majority of past studies of PAD
have either failed to find relationships between BMI and
ABI, or found evidence that higher BMI is associated with
lower PAD risk (Criqui & Aboyans, 2015). For instance,
working with US NHANES data, Selvin (2004) found that
obese individuals (BMI > 30 kg/m2) were roughly half as
likely to have PAD compared to individuals who were nor-
mal weight or underweight (BMI < 25 kg/m2). Similarly,
among 5084 participants (age > 65 years) in the US-based
Cardiovascular Health Study, the BMI was again signifi-
cantly related to lower PAD risk (Newman et al., 1993). As
in Cebu, a study in Thailand found BMI to be a significant
positive predictor of ABI, consistent with lower PAD risk
(Sritara et al., 2007).
Explanations for the finding of an apparent protective
relationship between measures like BMI or WC and PAD
risk in past studies have focused on the potential con-
founding role of smoking and/or poor health, both of which
may be associated with atherosclerosis progression while
also leading to weight loss (Criqui & Aboyans, 2015). In a
follow-up analysis of the US Cardiovascular Health Study
described above (Newman et al., 1993), Ix et al. (2011) lim-
ited analyses to healthy nonsmokers and found a positive
relationship between BMI and PAD risk in this subsample.
Although the prevalence of smoking is relatively low in our
sample, adjusting for smoking in models did modestly atten-
uate relationships between ABI and measures of adiposity,
pointing to the potential for similar confounding of associa-
tions in the CLHNS sample.
Availability of bioelectrical impedance data from the
2012 survey allowed us to calculate fat and fat free mass,
which provided additional insights into the relationship
between body composition and PAD risk. We found that
both height and lean mass were significant positive predic-
tors of ABI, and that the nonsignificant positive relationships
with adiposity measures were all weakened substantially by
their inclusion in models. In aging samples, reduced muscle
mass and strength have previously been shown to be related
to pro-inflammatory cytokines (Visser et al., 2002), reduced
insulin sensitivity (Srikanthan & Karlamangla, 2011), and
arterial stiffness (Ochi et al., 2010), hinting at possible
mechanisms that could contribute to these relationships. One
potential interpretation of our body composition findings is
that muscle mass has a protective relationship with ABI and
that the tendency for lean mass and measures of adiposity to
be positively related confounds associations with these other
measures. In follow-up analyses, we found that grip strength
was even stronger than lean mass as a positive predictor of
ABI, consistent with possible involvement of muscle and
strength in these relationships. These findings could help
explain the common reports, noted above, of positive rela-
tionships between measures of adiposity like BMI and the
ABI in other populations. If this finding is replicated and
shown to be causal, it also points to the potential importance
of promoting muscle mass, such as through resistance train-
ing (Hunter, McCarthy, & Bamman, 2004), as a means of
protecting against age-related development of PAD in older
women.
Several limitations of this study warrant mention. Most
notably, because this was a follow-up of a birth cohort study
that enrolled pregnant women in 1983, we focus solely on
women, and our findings should not be extrapolated to men.
Because our sample had a mean age of 55 years, prevalence
of PAD could rise further as the sample ages. Finally, this
study involved a single cross-sectional ABI measurement
and, due to the logistical constraints of clinic visits, involved
a convenience sub-sample of the full CLHNS sample.
Because the women included in the ABI sub-sample had
lower blood pressure and glucose values 10 years prior to
ABI measurement, when compared to women excluded from
the ABI sub-study (see Section 2), it is possible that the
prevalence of PAD that we document slightly underesti-
mates levels that would be seen in a representative sample
from Cebu. These study design issues limit our ability to
explore causal relationships longitudinally, and also limit the
sample's representativeness of the Cebu population from
which they were drawn.
In sum, we find evidence for a very low prevalence of
PAD in an aging cohort of women living in Metropolitan
Cebu, Philippines. These findings are consistent with the
low reported prevalence of the condition in a recent national
survey in the Philippines (FNRI-DOST, 2015b). Risk for
PAD was increased among smokers, among women taking
medications for CVD, and in relation to systolic blood pres-
sure. Fat free mass and grip strength were found to have sig-
nificant, protective relationships with ABI. Our findings are
most similar to a study in lowland Bolivia in which PAD
was absent, did not increase with age and was unrelated to
body composition or most CVD risk factors. We speculate
that shared features of the ecologies experienced by these
populations, perhaps including early infectious disease expo-
sure, could help explain these findings.
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